Cancer screening programmes in the Czech Republic and their results

Czech version

Authors: K. Hejcmanová ^1,2; O. Ngo ^1,2; R. Chloupková ^1,2; M. Ambrožová ^1,2; P. Dvořák ¹; V. Rybenská ¹; J. Daneš ³; Š. Suchánek ⁴; V. Dvořák ⁵; M. Koziar Vašáková ⁶; R. Zachoval ⁷; K. Hejduk ^1,2; L. Dušek ^1,2; O. Májek ^1,2
Authors‘ workplace: Národní screeningové centrum, Ústav zdravotnických informací a statistiky ČR, Praha ¹; Institut biostatistiky a analýz, LF MU, Brno ²; Radiodiagnostická klinika 1. LF UK a VFN v Praze ³; Oddělení gastrointestinální endoskopie, ÚVN Praha ⁴; Centrum ambulantní gynekologie a primární péče, Brno ⁵; Pneumologická klinika 1. LF UK a FTN Praha ⁶; Urologická klinika 3. LF UK a FTN Praha ⁷
Published in: Klin Onkol 2026; 39(Supplementum 1): 6-11
Category: Original Articles
doi: https://doi.org/10.48095/ccko2026S6

Overview

Background: Screening programmes are a key component of secondary prevention, with the aim of detecting disease at an early stage. In the Czech Republic, five cancer screening programmes are currently fully covered by public health insurance. These include screening for breast cancer, colorectal cancer and cervical cancer, early detection of lung and prostate cancer is also being piloted. The aim of this communication is to present nationwide programmes and the results of the evaluation of key performance indicators. Material and methods: Based on the data from the National Health Information System, screening programmes are regularly monitored and evaluated. The basic indicators are epidemiological characteristics, such as incidence and mortality, but also indicators of the quality of the screening programme, such as coverage of the target population or the proportion of people with abnormal screening test results. Results: Analytical outputs show that the incidence and mortality of colorectal and cervical cancer, where the goal is to detect precancerous lesions, are continuously decreasing. Breast cancer mortality is also declining, while incidence has been increasing over the long term, as the role of screening here is to detect cancer at an early stage. Coverage of the target population for breast and cervical cancer screening reaches up to 60%, while for colorectal cancer screening it is above 30%. As part of early detection of lung cancer, nearly 20,000 current or former smokers were examined over 3.5 years, and in more than 3% of cases, a positive finding was detected radiologically during the first screening episode, requiring further investigation. Approximately 250,000 men participated in early detection of prostate cancer over 1.5 years, and just under 9% were found to have elevated prostatic specific angigen levels. Conclusion: Screening programmes are available to the target population and fully covered by public health insurance. However, continuous monitoring and evaluation are essential, as are following international recommendations, developing the digitalization of healthcare, and providing ongoing education to both the lay and professional public. Available data demonstrate the effectiveness and positive population impact of screening programs.

Keywords:

secondary prevention – mass screening – data analysis

Sources

1. Májek O, Daneš J, Skovajsová M et al. Mamo.cz –⁠ Program screeningu karcinomu prsu v České republice. Ústav zdravotnických informací a statistiky ČR 2025. [online]. Dostupné z: https: //www.mamo.cz/.

2. Májek O, Suchánek Š, Zavoral M et al. Kolorektum.cz –Program screeningu kolorektálního karcinomu v České republice. Ústav zdravotnických informací a statistiky ČR 2025. [online]. Dostupné z: https: //www.kolorektum.cz/.

3. Májek O, Dvořák V, Dušek L et al. Cervix.cz –⁠ Program screeningu karcinomu děložního hrdla v České republice. Ústav zdravotnických informací a statistiky ČR 2025. [online]. Dostupné z: https: //www.cervix.cz.

4. Májek O, Koziar Vašáková M, Čierna Peterová I et al. PrevenceProPlice.cz –⁠ Program časného záchytu karcinomu plic. Praha: Ústav zdravotnických informací a statistiky ČR 2022. [online]. Dostupné z: https: //www.prevenceproplice.cz.

5. Koudelková M, Zachoval R, Ferda J et al. Prostascreening.cz –⁠ Program časného záchytu karcinomu prostaty. Praha: Ústav zdravotnických informací a statistiky ČR 2024. [online]. Dostupné z: https: //www.prostascreening.cz.

6. Majek O, Danes J, Skovajsova M et al. Breast cancer screening in the Czech Republic: time trends in performance indicators during the first seven years of the organised programme. BMC Public Health 2011; 11 : 288. doi: 10.1186/1471-2458-11-288.

7. Suchanek S, Majek O, Vojtechova G et al. Colorectal cancer prevention in the Czech Republic: time trends in performance indicators and current situation after 10 years of screening. Eur J Cancer Prev 2014; 23 (1): 18–26. doi: 10.1097/CEJ.0b013e328364f203.

8. Májek O, Dušková J, Dvořák V et al. Performance indicators in a newly established organized cervical screening programme: registry-based analysis in the Czech Republic. Eur J Cancer Prev 2017; 26 (3): 232–239. doi: 10.1097/CEJ.0000000000000236.

9. Ward B, Koziar Vašáková M, Robalo Cordeiro C et al. Important steps towards a big change for lung health: a joint approach by the European respiratory society, the European Society of Radiology and their partners to facilitate implementation of the European Union’s new recommendations on lung cancer screening. ERJ Open Res 2023; 9 (3): 00026-2023. doi: 10.1183/23120541.00026-2023.

10. Májek O, Babjuk M, Roobol MJ et al. How to follow the new EU council recommendation and improve prostate cancer early detection: the Prostaforum 2022 declaration. Eur Urol Open Sci 2023; 53 : 106–108. doi: 10.1016/j.euros.2023.05.011.

11. Hejduk K, Mandelová L, Ngo O et al. Národní screeningové centrum ÚZIS ČR. Praha: Ministerstvo zdravotnictví ČR a Ústav zdravotnických informací a statistiky ČR 2024. [online]. Dostupné z: https: //www.nsc.uzis.cz.

12. Májek O, Anttila A, Arbyn M et al. The legal framework for European cervical cancer screening programmes. Eur J Public Health 2019; 29 (2): 345–350. doi: 10.1093/eurpub/cky200.

13. Chloupková R, Ngo O, Ambrožová M et al. Národní screeningové centrum: Datový portál screeningových programů. Praha: Ministerstvo zdravotnictví ČR 2022. [online]. Dostupné z: https: //nsc-data.uzis.cz.

14. Ru Zhao Y, Xie X, de Koning HJ et al. NELSON lung cancer screening study. Cancer Imaging 2011; 11 (1A): S79–S84. doi: 10.1102/1470-7330.2011.9020.

15. European Union. Council Recommendation of 9 December 2022 on strengthening prevention through early detection: A new EU approach on cancer screening replacing Council Recommendation 2003/878/EC 2022/C 473/01. [online]. Available from: https: //eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX: 32022H1213 (01).

16. OECD. Health at a Glance 2025: OECD Indicators. [online]. Available from: https: //www.oecd.org/en/publications/health-at-a-glance-2025_8f9e3f98-en.html.